Aggredyne, a biomedical diagnostics firm involved in platelet function testing, raised $3 million in a Series A convertible preferred stock funding round. The Houston firm is preparing to apply for U.S. marketing approval for its laser-light scattering platelet aggregometer, AggreGuideTM A-100, and related blood platelet tests.